Kevin Kunzmann

A CDC analysis shows more doses were administered adults and adolescents than in previous years, while COVID-19 factors may have influenced the dip in shots among children.

In recognition of Lung Cancer Awareness Month, this episode featuring Dr. James Mulshine at Rush University explains the ins and outs of the improved 2021 lung cancer screening guidelines.

The Director of Retina Services at Wills Eye Hospital joins to discuss the historic FDA approval granted for a novel method of ophthalmic care: a permanent implant that allows for vision-saving formula therapy to treat the eye continually.

A geographical study shows patients in areas with lower income, education, and higher rates of ophthalmic disease may be a greater distance from a trial site.

The COLUMBUS-AMD trial suggests the investigative biosimilar could benefit patients newly diagnosed with nAMD.

A cost-based assessment of Protocol W and PANORAMA clinical data suggests diabetic retinopathy may be less costly to prevent than macular edema.

Bevacizumab-vikg was associated with statistically significant improvements in patient BCVA scores over a period of 12 months, according to phase 3 findings.

A meta-analysis comparison of dosing regimens for patients with nAMD show little difference in efficacy, but differences in patient involvement in care.

A phase 1 trial of the investigative drug suggests its promise in a novel strategy of managing patients with retinal fluid.

Findings from the phase 2 INFINITY suggest a more dose-dependent influence on safety outcomes in patients receiving sustained benefit for diabetic macular edema.

An update from the PIONEER trial shows the combination gene therapy and medical device strategy is safe and tolerable, while providing cases of improved light perception.

An AAO 2021 presentation highlighted the industrial design differences that could result in treatment overdoses with pre-filled syringes of aflibercept.

Early 2020 response to the pandemic was linked to many patients being lost to follow-up, and countries reported worse overall visual acuity among their patients.

New HAWK and HARRIER findings show patients with fluid-free visits reported greater benefit in BVCA while receiving anti-VEGF.

The FDA has yet to rule on twice-daily pill.

A cross-sectional analysis suggests children aged 5-7 years old may begin to reckon with the burdens of sickle cell disease, while toddlers and infants may not.

Triamcinolone acetonide injectable suspension has been approved for administration via the suprachoroidal pathway—located in the back of the eye.

The novel PDS implant will allow patients with retina disease to receive continuous anti-VEGF formulation for up to 6 months between refills.

The indication makes 6 to 11-year-old children with eosinophilic biomarkers or corticosteroid dependency eligible for the biologic add-on therapy.

ILD is a very broad category of chronic lung conditions with considerable nuance. Glassberg joins to discuss the roles of biomarkers, biopsies and drugs, as well as multidisciplinary clinics and stem cell therapy.

The novel method of administration is a first of its kind for the common chronic eye condition.

The new indication makes the quadrivalent Seqirus flu shot available for every US-eligible patient age group.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.

The indication came via the Premarket Tobacco Product Application, which requires evidence of public health benefit and company agreement to post-marketing strategies that avoid young users.

Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.

Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.

Veeral S. Sheth, MD, MBA, discusses what ophthalmologists will need to learn about PDS application for patients with AMD.

Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends in patients.